HOPE-3 Trial : Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease

HOPE-3 Trial : Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease

• In patients at intermediate risk for ASCVD (A 10-year risk of 10 to 20%, Framingham risk assessment tool) or borderline risk, use of additional risk stratifying tests like hsCRP and lipoprotein-associated phospholipase A2 is indicated.

• Consideration for statin therapy in patients at intermediate risk for CVD (AACE 2017 lipid guidelines)

Infographic

Reference

Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, Pais P, López-Jaramillo P, Leiter LA, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M, Sliwa K, Peters RJ, Held C, Chazova I, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Sanchez-Vallejo G, McKelvie R, Pogue J, Jung H, Gao P, Diaz R, Lonn E; HOPE-3 Investigators. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 2016 May 26;374(21):2021-31.

>